MX2009002820A - Conjugados polimericos de box-a de hmgb1 y variantes de box-a de hmgb1. - Google Patents

Conjugados polimericos de box-a de hmgb1 y variantes de box-a de hmgb1.

Info

Publication number
MX2009002820A
MX2009002820A MX2009002820A MX2009002820A MX2009002820A MX 2009002820 A MX2009002820 A MX 2009002820A MX 2009002820 A MX2009002820 A MX 2009002820A MX 2009002820 A MX2009002820 A MX 2009002820A MX 2009002820 A MX2009002820 A MX 2009002820A
Authority
MX
Mexico
Prior art keywords
hmgb1
box
polymer conjugates
variants
binding domain
Prior art date
Application number
MX2009002820A
Other languages
English (en)
Inventor
Silvano Fumero
Valentina Mainero
Silvio Traversa
Chiara Lorenzetto
Luca Beccaria
Sebastiano Morena
Original Assignee
Creabilis Therapeutics Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38969804&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009002820(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Creabilis Therapeutics Spa filed Critical Creabilis Therapeutics Spa
Publication of MX2009002820A publication Critical patent/MX2009002820A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)

Abstract

La presente invención se relaciona con conjugados poliméricos novedosos de variantes polipeptídicas del dominio de unión de alta afinidad Box-A de HMGB1 (HMGB1 Box-A) o de un fragmento biológicamente activo de HMGB1 Box-A. Además, la invención se relaciona con conjugados poliméricos novedosos de variante polipeptídicas del dominio de unión de alta afinidad Box-A HMGB1 (HMGB1 Box-A). Además, la presente invención se relaciona con el uso de los conjugados poliméricos de moléculas polipeptídicas de HMGB1 Box-A para diagnosticar, prevenir, aliviar y/o tratar patologías asociadas con HMGB1 extracelular y/o asociadas con incremento de la expresión de RAGE.
MX2009002820A 2006-09-15 2007-09-14 Conjugados polimericos de box-a de hmgb1 y variantes de box-a de hmgb1. MX2009002820A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06019362 2006-09-15
US90477607P 2007-03-05 2007-03-05
PCT/EP2007/008029 WO2008031612A1 (en) 2006-09-15 2007-09-14 Polymer conjugates of box-a of hmgb1 and box-a variants of hmgb1

Publications (1)

Publication Number Publication Date
MX2009002820A true MX2009002820A (es) 2009-06-04

Family

ID=38969804

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009002820A MX2009002820A (es) 2006-09-15 2007-09-14 Conjugados polimericos de box-a de hmgb1 y variantes de box-a de hmgb1.

Country Status (11)

Country Link
US (3) US8546547B2 (es)
EP (1) EP2068935B8 (es)
JP (3) JP2010503630A (es)
AU (1) AU2007296843C1 (es)
CA (1) CA2663300C (es)
HK (1) HK1134779A1 (es)
HR (1) HRP20110487T1 (es)
IL (1) IL197441A (es)
MX (1) MX2009002820A (es)
PL (1) PL2068935T3 (es)
WO (1) WO2008031612A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0911513A2 (pt) 2008-04-30 2016-07-12 Genomix Co Ltd métodos e agentes para coleta de células tronco da medula óssea funcionais in vivo com alta eficiência
US20120165244A1 (en) * 2008-10-30 2012-06-28 Hua-Lin Wu Methods for binding lewis y antigen
JP5467313B2 (ja) * 2009-09-28 2014-04-09 国立大学法人 岡山大学 アテローム動脈硬化抑制剤
CN101691580B (zh) * 2009-09-28 2012-02-15 中国人民解放军第三军医大学 人HMGB1 A box和酸性尾端的新型融合蛋白及其应用
RU2016135937A (ru) 2009-10-28 2018-12-11 Дженомикс Ко., Лтд. Средства для стимуляции регенерации тканей путем привлечения мезинхимных стволовых клеток и/или плюрипотентных стволовых клеток костного мозга в кровь
US20110123483A1 (en) * 2009-11-23 2011-05-26 Deutsches Krebsforschungszentrum Hmgb1 for cancer treatment
US8981025B2 (en) 2011-02-10 2015-03-17 Corning Incorporated Polymerizable catonic peptide monomers and polymers
KR102113809B1 (ko) 2011-04-26 2020-05-21 가부시키가이샤 스템림 조직 재생을 유도하기 위한 펩티드 및 그의 이용
EP2877248B1 (en) 2012-07-26 2017-10-25 Ospedale San Raffaele S.r.l. Hmgb1 variants and uses thereof
GB201508337D0 (en) 2015-05-15 2015-06-24 Hmgbiotech S R L Novel peptides
US11274132B2 (en) 2015-12-11 2022-03-15 Ruprecht-Karls-Universität Heidelberg Combined preparations of PKM2 modulators and HMGB1
JP7182162B2 (ja) 2017-01-27 2022-12-02 株式会社ステムリム 心筋症、陳旧性心筋梗塞および慢性心不全の治療薬
WO2019107530A1 (ja) * 2017-12-01 2019-06-06 株式会社ステムリム 炎症性腸疾患の治療薬
CA3114905A1 (en) * 2018-10-05 2020-04-09 Research Institute At Nationwide Children's Hospital Hmgb1 protein derivatives for the removal of biofilms
US20210386823A1 (en) * 2018-10-25 2021-12-16 Osaka University Therapeutic agent for cartilage disorder
US11684653B2 (en) * 2019-03-06 2023-06-27 The Cleveland Clinic Foundation Compositions and method for reducing virulence of microorganisms
JP7500727B2 (ja) 2019-12-18 2024-06-17 エフ． ホフマン－ラ ロシュ アーゲー 連続的な標識スキームを使用した合成による配列決定方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2524586B2 (ja) * 1985-06-26 1996-08-14 シタス コーポレイション ポリマ−接合を利用する医薬組成物用蛋白質の可溶化
CN1329082C (zh) 1998-10-16 2007-08-01 拜奥根Idec马萨诸塞公司 干扰素－β－1a的聚合物缀合物及其使用
GEP20063916B (en) 2001-02-01 2006-09-11 Biogen Idec Inc Polymer conjugates of neublastin and methods of using same
ITMI20010562A1 (it) 2001-03-16 2002-09-16 Marco E Bianchi Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
JP2005512507A (ja) 2001-05-15 2005-05-12 ノース・ショア−ロング・アイランド・ジューイッシュ・リサーチ・インスティテュート 抗炎症剤としてのｈｍｇフラグメントの使用
JP2006510619A (ja) * 2002-11-20 2006-03-30 クリティカル セラピューティクス，インコーポレイテッド 抗炎症剤としてのｈｍｇｂ断片の使用
DE60326774D1 (de) 2002-12-19 2009-04-30 Nektar Therapeutics Al Corp Konjugate von cyanovirin-varianten und einem polyalkylenoxid
ATE459647T1 (de) 2003-04-15 2010-03-15 Glaxosmithkline Llc Humane il-18 substitutionsmutanten und deren konjugate
WO2006012373A2 (en) * 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Combination therapies of hmgb and complement inhibitors against inflammation
NZ553809A (en) * 2004-09-03 2010-03-26 Creabilis Therapeutics Spa Use of polypeptides obtained through systematic mutations of single amino acids of human and non-human box-A of HMGB1 to prevent and/or antagonize pathologies induced by HMGB1
CN103690936A (zh) 2004-12-22 2014-04-02 Ambrx公司 经修饰的人类生长激素
EP1919979B2 (en) 2005-08-25 2017-03-29 Creabilis Therapeutics S.P.A. Polymer conjugates of k-252a and derivatives thereof

Also Published As

Publication number Publication date
EP2068935B1 (en) 2011-04-13
CA2663300C (en) 2014-10-07
EP2068935B8 (en) 2011-09-14
US20140065094A1 (en) 2014-03-06
AU2007296843A1 (en) 2008-03-20
CA2663300A1 (en) 2008-03-20
WO2008031612A1 (en) 2008-03-20
PL2068935T3 (pl) 2011-11-30
US20170304398A1 (en) 2017-10-26
JP2010503630A (ja) 2010-02-04
IL197441A (en) 2013-07-31
AU2007296843B2 (en) 2012-02-23
AU2007296843C1 (en) 2012-08-16
US8546547B2 (en) 2013-10-01
US9707298B2 (en) 2017-07-18
HK1134779A1 (en) 2010-05-14
JP2017200930A (ja) 2017-11-09
EP2068935A1 (en) 2009-06-17
JP2015193646A (ja) 2015-11-05
HRP20110487T1 (hr) 2011-08-31
IL197441A0 (en) 2009-12-24
US20090324677A1 (en) 2009-12-31

Similar Documents

Publication Publication Date Title
MX2009002820A (es) Conjugados polimericos de box-a de hmgb1 y variantes de box-a de hmgb1.
MX2009007290A (es) Compuestos agonistas del receptor de la proteina 1 similar al glucagon.
BE2021C505I2 (es)
BRPI0820500A2 (pt) Variantes de alfa-amilase de bacillus sp. Ts-23 com propriedades alteradas
MX2007015935A (es) Agentes y metodos basados en el uso del dominio eda de la fibronectina.
MY156767A (en) Anti-angiogenic compounds
BRPI0716649A2 (pt) poliuretanos antiestÁticos e eletricamente condutores
DE602007010664D1 (de) P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen
NZ588033A (en) Methods of treating a mif-mediated disorder
TW201613969A (en) IL-17 binding proteins
ATE505205T1 (de) Polymerkonjugate von box-a von hmgb1 und box-a- varianten von hmgb1
MX2012003939A (es) Fusiones y conjugados de farmaco.
NO20091181L (no) Anti-C5AR-antistoffer med forbedrede egenskaper
MA32190B1 (fr) Anticorps dirigés contre l'angiopoïétine 1 et l'angiopoïétine 2 et leur utilisation
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
WO2008073162A3 (en) Lysine acetylation sites
ATE449097T1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
EA201070179A1 (ru) Антиген, связанный с вариантами рака легкого и лимфомами
ATE442416T1 (de) Polyoxymethylen-zusammensetzungen, deren herstellung und verwendung
WO2007101698A3 (en) Modified molecules which promote hematopoiesis
NO20084795L (no) Fremgangsmate for a behandle, diagnostisere eller detektere kreft
EA200702529A1 (ru) Фунгицидная комбинация биологически активных веществ
WO2007064727A3 (en) Penetrabodies: receptor-mediated targeted delivery of functionally-active human antibody fragments into cytosol for the treatment of chronic infections and diseases
ATE465296T1 (de) Biopolymere als nassfestmittel
ATE497976T1 (de) Spezifisch an vygfvracl-hla-a24 bindende t-zellen-rezeptoren

Legal Events

Date Code Title Description
FG Grant or registration